Immunovant, Inc. Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended September 30, 2023. Immunovant is a clinical-stage biopharmaceutical company developing the anti-FcRn antibodies batoclimab and IMVT-1402 for autoimmune diseases. The financial statements are unaudited and prepared under U.S. GAAP. The company has one operating segment and has generated no product revenue.
Financial Performance and Position
| Metric | Three months ended September 30, 2023 | Three months ended September 30, 2022 | Six months ended September 30, 2023 | Six months ended September 30, 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $48.0 million | $37.7 million | $98.5 million | $66.2 million |
| Acquired in-process R&D | $0 | $0 | $12.5 million | $0 |
| General and administrative expense | $13.8 million | $11.9 million | $29.2 million | $23.8 million |
| Total operating expenses | $61.8 million | $49.6 million | $140.3 million | $90.0 million |
| Net loss | $58.7 million | $47.9 million | $132.6 million | $88.3 million |
| Net loss per share | $0.45 | $0.41 | $1.01 | $0.76 |
| Net cash used in operating activities | Not separately disclosed | Not separately disclosed | $107.4 million | $86.0 million |
- Interest income was $3.6 million in the quarter and $7.6 million for the six-month period, compared with $1.2 million and $1.2 million, respectively, in the prior-year periods.
- Cash and cash equivalents were $269.9 million at September 30, 2023, compared with $376.5 million at March 31, 2023. Money market funds represented $254.1 million of the September 30 balance.
- Accumulated deficit was $698.9 million at September 30, 2023. Total stockholders’ equity was $251.8 million and total liabilities were $40.3 million.
- The filing does not report outstanding borrowings or material debt financing. Liabilities primarily consisted of accounts payable, accrued expenses and operating lease liabilities.
- Operating margin and other profitability margins are not meaningful because the company has no revenue and remains loss-making.
Material Changes Versus the Prior Comparable Period
- Second-quarter research and development expense increased $10.2 million, or approximately 27%, primarily due to higher IMVT-1402 development costs and increased personnel-related costs.
- Six-month research and development expense increased $32.4 million, or approximately 49%. IMVT-1402 costs increased $19.1 million, while batoclimab program-specific costs increased $5.7 million.
- General and administrative expense increased $2.0 million in the quarter and $5.4 million for the six-month period, driven primarily by personnel, market research and information technology costs.
- Six-month operating expenses included a $12.5 million acquired in-process research and development charge for two development and regulatory milestones under the HanAll Agreement.
- Net loss increased $10.7 million in the quarter and $44.3 million for the six-month period. Higher interest income partially offset the increase in operating expenses.
- Six-month operating cash use increased $21.4 million year over year, reflecting higher clinical development spending and operating losses.
- Common shares outstanding increased to 131.4 million at September 30, 2023 from 130.3 million at March 31, 2023. Equity compensation and option exercises also increased the potential share count.
Development, Outlook, Risks and Unusual Items
- The FDA cleared the IND for IMVT-1402 during the quarter ended June 30, 2023, and the company initiated a Phase 1 trial in healthy adults in New Zealand. Initial data showed a 63% reduction in mean total IgG after four weekly 300 mg doses, with no statistically significant reductions in albumin or increases in LDL cholesterol at measured time points. The company expected 600 mg cohort data in November 2023. These are preliminary clinical results and may change.
- Batoclimab is being developed in myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy and Graves’ disease. Management expected initial Graves’ disease results by the end of calendar 2023, CIDP open-label data in the first half of calendar 2024, myasthenia gravis top-line data in the second half of calendar 2024 and thyroid eye disease top-line results in the first half of calendar 2025.
- Management expects research and development expenses to continue increasing as clinical trials advance, manufacturing expands and regulatory preparations proceed.
- In October 2023, after the reporting date, the company completed a public offering and concurrent private placement at $38.00 per share. Net proceeds were approximately $466.6 million. RSL purchased 1.526 million public-offering shares and 4.474 million private-placement shares.
- In November 2023, the company entered into a new at-the-market facility allowing sales of up to $150.0 million of common stock. No shares had been sold under the facility as of the filing.
- Management stated that September 30 cash, together with the October financing proceeds, was expected to fund operating and capital requirements for at least the next 12 months and in the long term beyond the next 12 months. The company also stated that current funds will not be sufficient to complete all development and potential commercial-launch activities.
- Remaining minimum purchase commitments under the Samsung manufacturing agreement were approximately $18.7 million, including $3.5 million expected during the remainder of fiscal 2024, $2.5 million in fiscal 2025 and $12.7 million in fiscal 2026.
- The HanAll Agreement includes potential future milestone payments of up to $420.0 million after $32.5 million of milestones achieved as of September 30, 2023, as well as tiered royalties ranging from the mid-single digits to mid-teens percentage of net sales if products are commercialized.
- A putative securities class action concerning statements about batoclimab safety remained pending. The company had not accrued a liability because it could not reasonably estimate potential losses or determine whether an unfavorable outcome was probable.
- Key risks include clinical-trial failure or delay, adverse lipid or albumin effects associated with batoclimab, regulatory approval uncertainty, reliance on HanAll, contract manufacturers and CROs, competition from other FcRn therapies, additional financing needs and potential dilution.
- Roivant Sciences Ltd. beneficially owned approximately 55.2% of voting power as of November 3, 2023 and therefore continued to exercise significant control over stockholder and board matters.
Investor Verification Checklist
- Verify the final results, statistical significance, safety profile and durability of the IMVT-1402 Phase 1 data, including the 600 mg cohort.
- Track enrollment, timelines, endpoints and safety findings for batoclimab trials in myasthenia gravis, thyroid eye disease, CIDP and Graves’ disease.
- Reconcile post-quarter financing proceeds, shares issued and resulting dilution, including RSL’s ownership percentage after the October offering.
- Assess cash burn against the stated runway and determine when additional equity, debt or partnership financing may be required.
- Monitor future HanAll milestone obligations, royalties and the approximately $18.7 million Samsung manufacturing commitment.
- Review developments in the securities litigation and any potential impact on liabilities, cash flows or management resources.
- Evaluate the ability of batoclimab and IMVT-1402 to differentiate themselves from approved or developing FcRn competitors and alternative autoimmune treatments.